The Summit on Breakthrough Therapies for Addiction

Ibogaine has shown promise as a treatment for substance use disorders, yet its mechanisms and clinical development have been constrained by safety concerns. In this session, Dr. Deborah Mash will discuss her extensive research investigating ibogaine's metabolite noribogaine, which offers a longer-acting psychoactive profile without cardiovascular toxicity. She will explain noribogaine’s unique mechanisms of action in reducing drug cravings, blocking withdrawal symptoms, and modulating stress pathways implicated in addiction. Attendees will gain key insights into ibogaine derivatives as a safer, more therapeutically powerful option for addiction treatment.